OncoMatch/Clinical Trials/NCT06900647
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Is NCT06900647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for metastatic breast cancer.
Treatment: Bortezomib (B) · Cisplatin (CDDP) · Bortezomib (B) · Bortezomib (B) · Cisplatin (CDDP) — This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
anc ≥1.5×109/l, plt ≥75×109/l, hb ≥85g/l (no blood transfusion and blood products within 14 days, no use of g-csf and other hematopoietic stimulating factors for correction)
Kidney function
bun and cr ≤1×uln or endogenous creatinine clearance ≥50ml/min (cockcroft-gault formula)
Liver function
tbil <1.5×uln, alt, ast <2.5×uln, alt, ast <5×uln for patients with liver metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06900647 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages